2:
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.
J Infect Dis. 2003 Jul 15;188(2):327-38. Epub 2003 Jul 9.
PMID: 12854090 [PubMed - indexed for MEDLINE]
Related Articles
4:
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA.
Vaccine. 2006 Aug 14;24(33-34):5937-49. Epub 2006 Jun 19.
PMID: 16828940 [PubMed - indexed for MEDLINE]
Related Articles
7:
Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast.
Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, Neeper MP, Schultz LD, Shaw AR, Jansen KU.
J Infect Dis. 1997 Nov;176(5):1141-5.
PMID: 9359711 [PubMed - indexed for MEDLINE]
Related Articles
10:
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR.
J Natl Cancer Inst. 2001 Feb 21;93(4):284-92.
PMID: 11181775 [PubMed - indexed for MEDLINE]
Related Articles
13:
Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD, Bontkes HJ, Walboomers JM, Coursaget P, Stukart MJ, Dupuy C, Kueter E, Verheijen RH, Helmerhorst TJ, Duggan-Keen MF, Stern PL, Meijer CJ, Scheper RJ.
J Gen Virol. 1999 Feb;80 ( Pt 2):399-408.
PMID: 10073700 [PubMed - indexed for MEDLINE]
Related Articles
14:
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.
Cancer Immunol Immunother. 2004 Jul;53(7):642-50. Epub 2004 Feb 17.
PMID: 14985860 [PubMed - indexed for MEDLINE]
Related Articles
17:
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G; GlaxoSmithKline HPV Vaccine Study Group.
Lancet. 2004 Nov 13-19;364(9447):1757-65.
PMID: 15541448 [PubMed - indexed for MEDLINE]
Related Articles